Pharma Dynamics (Pty) Ltd

Belkins
Pharma Dynamics is the country’s leader in cardiovascular medication since 2012 - both in terms of value and volume – and is the fastest growing generic pharmaceutical company in South Africa. The organisation celebrates 16 years of improving the quality of life for South Africans after entrenching its mark in the industry with the launch of Amloc and Bilocor – SA’s two top selling anti-hypertensives. Today, Pharma Dynamics is active in more than 27 therapeutic areas, which include Central Nervous System (CNS), Female Healthcare, antimicrobial, pain and GIT categories, and it also supplies a range of Over the Counter (OTC) products.

Related News

PHARMA TECH

GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42,AN FXR AGONIST

Gannex | December 14, 2020

news image

Gannex, an entirely claimed organization of Ascletis Pharma Inc. (HKEX:1672) and completely committed to the R&D and commercialization of new medications in the field of NASH, reported today that it got Fast Track assignment from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug applicant ASC42. The U.S. FDA's Fast Track advancement program is intended to encourage the turn of events and speed up the survey of medications that ha...

Read More

PHARMACY MARKET

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

news image

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More

CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

Business Wire | March 17, 2020

news image

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Gro...

Read More

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

news image

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More
news image

PHARMA TECH

GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42,AN FXR AGONIST

Gannex | December 14, 2020

Gannex, an entirely claimed organization of Ascletis Pharma Inc. (HKEX:1672) and completely committed to the R&D and commercialization of new medications in the field of NASH, reported today that it got Fast Track assignment from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug applicant ASC42. The U.S. FDA's Fast Track advancement program is intended to encourage the turn of events and speed up the survey of medications that ha...

Read More
news image

PHARMACY MARKET

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More
news image

CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

Business Wire | March 17, 2020

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round – ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund – joined the financing. In conjunction with the financing, Peter Svennilson, founder and managing partner of The Column Gro...

Read More
news image

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us